Filing Flows

Filing Flows › Companies › Fate Therapeutics › Cash flow

Fate Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$27.8M in Q3 2026 · −$107M over twelve months

Operating cash flow−$27.8M
Free cash flow−$27.8M

Analysis

In Q3 2026, Fate Therapeutics generated −$27.8M of operating cash flow. That is $1.2M less than in Q3 2025 (−$26.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$105M; the largest uses were operating cash flow ($105M), capital spending ($1.5M); besides operations, cash came from other investing ($93.9M), other financing ($10.6M); the cash balance fell by $1.8M.

Operating cash flow was −$27.8M against net income of −$30.7M. The largest differences: stock-based pay +$2.7M, depreciation & amortization +$2.7M, prepaid and other assets −$1.2M.

Free cash flow

Fate Therapeutics: free cash flow by quarterFate Therapeutics: free cash flow by quarter−$27.9MQ4 2024−$35.0MQ1 2025−$25.9MQ2 2025−$26.6MQ3 2025−$24.5MQ4 2025−$31.1MQ1 2026−$23.5MQ2 2026−$27.8MQ3 2026
Operating cash flow less capital spending.
Fate Therapeutics: operating cash flow against capital spendingFate Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$27.8M$98KQ4 2024−$33.8M$1.2MQ1 2025−$24.6M$1.4MQ2 2025−$24.4M$2.2MQ3 2025−$23.3M$1.2MQ4 2025−$30.8M$239KQ1 2026−$23.4M$80KQ2 2026−$27.8M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$27.8M, Capital spending $0.

Capital allocation, year by year

Fate Therapeutics: where the cash came from (up) and went (down), by fiscal yearFate Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$163MFY2021: Shares issued $432MFY2021: Capital spending −$50.7M$432MFY2021FY2022: Operating cash flow −$248MFY2022: Shares issued $9.2MFY2022: Capital spending −$35.6M$9.2MFY2022FY2023: Operating cash flow −$132MFY2023: Shares issued $85KFY2023: Capital spending −$6.2M$85KFY2023FY2024: Operating cash flow −$123MFY2024: Shares issued $74.8MFY2024: Capital spending −$730K$74.8MFY2024FY2025: Operating cash flow −$106MFY2025: Asset sales $362KFY2025: Capital spending −$6.0M$362KFY2025
Over these 5 years operating cash flow totalled −$772M; the largest uses were operating cash flow ($772M) and capital spending ($99.1M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$139M
Debtnone
Net cash$139M
Cash runway16 months

Fate Therapeutics is burning cash: its operations consume cash, a free cash flow of −$107M a year at the current rate against $139M of cash and investments: a runway of about 16 months before any new financing.

Where the cash came from and went

Fate Therapeutics: sources (+) and uses (−) of cash, Q3 2026Fate Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$27.8MOther investing$26.8MShares issued$7.6MCash drawn (+) / kept (−)−$6.6MNot reconciled−$93K
Fate Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Fate Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$105MOther investing$93.9MOther financing$10.6MCash drawn (+) / kept (−)$1.8MCapital spending−$1.5MShares issued$435KAsset & business sales$237K

From profit to cash

Fate Therapeutics: net income to operating cash flow, Q3 2026Fate Therapeutics: net income to operating cash flow, Q3 2026Net income−$30.7MDepreciation & amortization$2.7MStock-based pay$2.7MReceivables$224KPayables−$127KDeferred revenue$1KPrepaid and other assets−$1.2MOperating cash flow−$27.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$27.8M—$7.6M−$6.6M−$27.8M
Q2 2026−$23.4M−$80K—$7.1M−$23.5M
Q1 2026−$30.8M−$239K—$7.2M−$31.1M
Q4 2025−$23.3M−$1.2M—−$6.0M−$24.5M
Q3 2025−$24.4M−$2.2M—$627K−$26.6M
Q2 2025−$24.6M−$1.4M—$3.7M−$25.9M
Q1 2025−$33.8M−$1.2M—−$8.9M−$35.0M
Q4 2024−$27.8M−$98K—$1.9M−$27.9M

Fate Therapeutics: income statement and cash flow

Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year). The chart follows the revenue to costs, profit and cash.

Fate Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.